This research reviews the current state of affairs in the fast-growing area of direct-to-consumer marketing of genetic tests. The authors identify the unique nature of genetic tests and the ensuing consumer vulnerability. They also present a comprehensive examination of the current legal environment and an empirical analysis of genetic testing companies’ online marketing practices. On the basis of the analysis and review, they make a set of policy recommendations that consists of consumer education, physician intervention and education, and direct regulation of marketing activities, especially as they relate to the online medium.
AlbaJoseph W., and Wesley HutchinsonJ. (1987), “Dimensions of Consumer Expertise,”Journal of Consumer Research, 13 (4), 411–54.
2.
AlbaJoseph W., and Wesley HutchinsonJ. (2000), “Knowledge Calibration: What Consumers Know and What They Think They Know,”Journal of Consumer Research, 27 (2), 123–56.
AndrewsLori B., JaneE. Fullarton, NeilA. Holtzman, and ArnoG. Muotulsky (1994), Assessing Genetic Risks: Implications for Health and Social Policy.Washington, DC: National Academy Press.
5.
AutonFrank (2004), “The Advertising of Pharmaceuticals Direct to Consumers: A Critical Review of the Literature and Debate,”International Journal of Advertising, 23 (1), 5–52.
6.
BagozziRichard P., GopinathMahesh, and PrashanthU. Nyer (1999), “The Role of Emotion in Marketing,”Journal of the Academy of Marketing Science, 27 (2), 184–206.
7.
BayleyCarol (2004), “The Challenge of Physician Education in Genetics,” in Genetics and Ethics: An Interdisciplinary Study, MagillGerard, ed. St. Louis: St. Louis University Press, 176–85.
8.
BurkeWylie (2004), “Genetic Testing in Primary Care,”Annual Review of Genomics and Human Genetics, 5, 1–14.
9.
BurkeDavid Atkins, GwinnMarta, GuttmacherAlan, HaddowJames, LauJoseph (2002), “Genetic Test Evaluation: Information Needs of Clinicians, Policy Makers, and the Public,”American Journal of Epistemology, 156 (4), 311–18.
10.
CalfeeJohn E. (2002), “Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs,”Journal of Public Policy & Marketing, 21 (Fall), 174–93.
11.
CellaD., HughesC., PetermanA., ChangC., PeshkinB.N., SchwartzM.D. (2002), “A Brief Assessment of Concerns Associated with Genetic Testing for Cancer: The Multidimensional Impact of Cancer Risk Assessment (Micra) Questionnaire,”Health Psychology, 21 (6), 564–72.
12.
CharnockD., Sasha ShepperdG. Needham, and GannR. (1999), “Discern: An Instrument for Judging the Quality of Written Consumer Health Information on Treatment Choices,”Journal of Epidemiology and Community Health, 53 (2), 105–11.
13.
ChoyAngela, HudsonZoe, PrittsJoy, and GoldmanJanlori (2001), “Exposed Online: Why the New Federal Health Privacy Regulation Doesn't Offer Much Protection to Internet Users,” report of the PEW Internet & American Life, (November), (accessed May 31, 2008), [available at http://www.pewinternet.org/pdfs/PIP_HPP_HealthPriv_report.pdf].
14.
ClaytonEllen Wright (2004), “Policy Challenges: Ethical, Legal, and Social Implications of Genetics,” in Genetics and Ethics: An Interdisciplinary Study, MagillGerard, ed. St. Louis: St. Louis University Press, 23–34.
CohenJoshua P., PaquetteCherie, and CatherineP. Cairns (2005), “Switching Prescription Drugs to Over the Counter,”British Medical Journal, 330 (7481), 39–40.
17.
ConradPeter (2002), “Genetics and Behavior in the News: Dilemmas of a Rising Paradigm,” in The Double-Edged Helix: Social Implications of Genetics in a Diverse Society, JosephS. Alper, ArdCatherine, AschAdrienne, and BeckwithJon, eds. Baltimore: Johns Hopkins University Press, 151–74.
18.
De Melo-MartinImmaculada (2006a), “Furthering Injustice Against Women: Genetic Information, Moral Obligations, and Gender,”Bioethics, 20 (6), 301–307.
19.
De Melo-MartinImmaculada (2006b), “Genetic Testing: The Appropriate Means to the Desired Goal,”Journal of Bioethical Inquiry, 3 (3), 167–77.
20.
DonohueJulie M., CevascoMarisa, and MeredithB. Rosenthal (2007), “A Decade of Direct-to-Consumer Advertising of Prescription Drugs,”New England Journal of Medicine, 357 (7), 673–81.
21.
EdellJulie A., and BurkeMarian Chapman (1987), “The Power of Feelings in Understanding Advertising Effects,”Journal of Consumer Research, 14 (3), 421–33.
22.
EntwhistleVikki A., SheldonT.A., SowdenA.J., and WattI.S. (1996), “Supporting Consumer Involvement in Decision-Making: What Constitutes Quality in Consumer Health Information,”International Journal of Quality in Health Care, 8 (5), 425–37.
23.
FDA Amendments Act (2007), Public Law No. 110-85 § 1103, 121 Stat. 824.
Genetic Information Nondiscrimination Act (2008), Public Law 110-233.
29.
GoddardKatrina, MooreCynthia, OttmanDenae, SzegdaKathleen, BradleyLinda, and KhouryMuin (2007), “Awareness and Use of Direct-to-Consumer Nutrigenomic Tests,”Genetics IN Medicine, 9 (8), 510–17.
30.
GollustSarah E., HullSara Chandros, and BenjaminS. Wilfond (2002), “Limitations of Direct-to-Consumer Advertising for Clinical Genetic Testing,”Journal of the American Medical Association, 288 (14), 1762–67.
31.
GollustBenjamin S. Wilfond, and HullSara Chandros (2003), “Direct-to-Consumer Sales of Genetic Services on the Internet,”Genetics in Medicine, 5 (4), 332–37.
Health Insurance Portability and Accountability Act (1996), 45 CFR § 164.102-164.534.
37.
HeatherJustin Lee (2001), “Liability for Direct-to-Consumer Advertising and Drug Information on the Internet,”Defense Counsel Journal, 68 (4), 412–20.
38.
HerelSuzanne (2002), “Research Questions Breast Cancer Risk: Report Suggests Mutant Gene May Not Warrant Mastectomy,”San Francisco Chronicle, (August 21), A1.
39.
HofmanKaren, EllenS. Tambor, GaryA. Chase, GellerGail, RuthR. Faden, and NeilA. Holtzman (1993), “Physicians’ Knowledge of Genetics and Genetic Tests,”Academic Medicine, 68 (8), 625–32.
40.
HudsonKathy, GailH. Javitt, BurkeWylie, and ByersPeter (2007), “ASHG Statement on Direct-to-Consumer Genetic Testing in the United States,”American Journal of Human Genetics, 81 (3), 635–37.
41.
JacobsLori R. (1998), “Prescription to Over-the-Counter Drug Reclassification,”American Family Physician, 57 (9), 2209–2214.
42.
JavittGail H. (2007), “In Search of a Coherent Framework: Options for FDA Oversight of Genetic Tests,”Food and Drug Law Journal, 62 (4), 617–52.
43.
JavittGail H., and HudsonKathy (2006a), “Federal Neglect: Regulation of Genetic Testing,”Issues in Science and Technology, 22 (3), 59–66.
LaTourMichael S., RobinL. Snipes, and SaraJ. Bliss (1996), “Don't Be Afraid to Use Fear Appeals: An Experimental Study,”Journal of Advertising Research, 36 (2), 59–67.
49.
LeeThomas H., and TroyenA. Brennan (2002), “Direct-to-Consumer Marketing of High-Technology Screening Tests,”New England Journal of Medicine, 346 (7), 529–31.
50.
LermanCaryn, and AlexandraE. Shields (2004), “Genetic Testing for Cancer Susceptibility: The Promise and the Pitfalls,”Nature Reviews Cancer, 4 (3), 235–41.
51.
LexchinJoel, and MintzesBarbara (2002), “Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No,”Journal of Public Policy & Marketing, 21 (Fall), 194–201.
52.
LiuYifei, WilliamR. Doucette, KarenB. Farris, and NayakankuppamDhananjay (2005), “Drug Information-Seeking Intention and Behavior After Exposure to Direct-to-Consumer Advertisement of Prescription Drugs,”Research in Social and Administrative Pharmacy, 1 (2), 251–69.
53.
MaciasWendy, and LewisLiza Stavchansky (2005), “How Well Do Direct-to-Consumer, DTC, Prescription Drug Web Sites Meet FDA Guidelines and Public Policy Concerns?”Health Marketing Quarterly, 22 (4), 45–71.
54.
MainKelley J., JenniferJ. Argo, and BruceA. Huhmann (2004), “Pharmaceutical Advertising in the USA: Information or Influence?”International Journal of Advertising, 23 (1), 119–42.
55.
McCabeLinda L., and EdwardR.B. McCabe (2004), “Direct-to-Consumer Genetic Testing: Access and Marketing,”Genetics IN Medicine, 6 (1), 58–59.
56.
MunsonRonald (2007), “Genetize Me! The Case for Direct-to-Consumer Genetic Testing,” in Ethics of Genetic Commerce, KolbRobert, ed. Boston: Blackwell Publishing, 55–69.
National Institutes of Health Task Force on Genetic Testing (1997), “Final Report of the Task Force on Genetic Testing,” (accessed August 4, 2007), [available at http://www.genome.gov/10001733].
59.
NeuendorfKimberly A. (2002), The Content Analysis Guidebook.Thousand Oaks, CA: Sage Publications.
60.
PinesWayne L. (1999), “A History and Perspective on Direct-to-Consumer Promotion,”Food and Drug Law Journal, 54 (4), 489–518.
61.
RacineEric, van Der LoosHZ Adriaan, and IllesJudy (2007), “Internet Marketing of Neuroproducts: New Practices and Healthcare Policy Challenges,”Cambridge Quarterly of Healthcare Ethics, 16 (2), 181–94.
62.
RingoldDebra Jones (2005), “Vulnerability in the Marketplace: Concepts, Caveats, and Possible Solutions,”Journal of Macro-marketing, 25 (2), 202–214.
63.
RosemanIra J. (1991), “Appraisal Determinants of Discrete Emotions,”Cognition and Emotion, 5 (3), 161–200.
64.
Securities and Exchange Commission (2000), “SEC Interpretation: Use of Electronic Media,” 17 CFR Parts 231, 241, and 271.
65.
SewakSaurabh S., NoelE. Wilkin, JohnP. Bentley, and MickeyC. Smith (2005), “Direct-to-Consumer Advertising via the Internet: The Role of Web Site Design,”Research in Social and Administrative Pharmacy, 1 (2), 289–309.
66.
ShepperdSasha, FarndonPeter, GraingeVivian, OliverSandy, ParkerMichael, PereraRafael (2006), “Discern-Genetics: Quality Criteria for Information on Genetic Testing,”European Journal of Human Genetics, 14 (7), 1179–88.
67.
SilbergWilliam, GeorgeD. Lundberg, and RobertA. Musacchio (1997), “Assessing, Controlling, and Assuring the Quality of Medical Information on the Internet,”Journal of the American Medical Association, 277 (15), 1244–45.
68.
TapscottDon, and AnthonyD. Williams (2006), Wikinomics: How Mass Collaboration Changes Everything.New York: Portfolio.
TaylorMatthew R.G., JaniceG. Edwards, and KuLisa (2006), “Lost in Transition: Challenges in the Expanding Field of Adult Genetics,”American Journal of Medical Genetics: Part C: Seminars in Medical Genetics, 142C (4), 294–303.
71.
WaackKatherine E., MichaelE. Ernst, and MarkA. Graber (2004), “Informational Content of Official Pharmaceutical Industry Web Sites About Treatments for Erectile Dysfunction,”Annals of Pharmacotherapy, 38 (12), 2029–2034.
WilkesMichael S., RobertA. Bell, and RichardL. Kravitz (2000), “Direct-to-Consumer Prescription Drug Advertising: Trends, Impact, and Implications,”Health Affairs, 19 (2), 110–28.
74.
Williams-JonesBryn (2003), “Where There's a Web, There's a Way: Commercial Genetic Testing and the Internet,”Community Genetics, 6 (1), 46–57.
75.
WolfeSidney M. (2002), “Direct-to-Consumer Advertising: Education or Emotion Promotion?”New England Journal of Medicine, 346 (7), 524–26.
76.
WoloshinSteven, LisaM. Schwartz, TremmelJennifer, and Gilbert WelchH. (2001), “Direct-to-Consumer Advertisements for Prescription Drugs: What Are Americans Being Sold?”The Lancet, 358 (October), 1141–46.
